CG Oncology, Inc. (CGON) — Quarterly Report

Key Insights

• The filing content appears to be corrupted or improperly formatted XML/XBRL data without readable financial statements, making it impossible to extract specific revenue, expense, or profitability metrics for Q1 2026.
• Multiple references to stock options, equity awards, and employee stock purchase plans indicate active compensation through equity, which could signal dilution to existing shareholders.
• The presence of numerous subsidiary and partnership members (Lepu Biotech, Kissei Pharmaceutical, Biovire) suggests CG Oncology maintains a complex corporate structure with multiple collaboration relationships that require monitoring.